BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$75.06 USD
+0.63 (0.85%)
Updated May 29, 2024 04:00 PM ET
Pre-Market: $76.37 +1.31 (1.75%) 8:58 AM ET
3-Hold of 5 3
C Value F Growth D Momentum D VGM
Brokerage Reports
BioMarin Pharmaceutical Inc. [BMRN]
Reports for Purchase
Showing records 161 - 180 ( 814 total )
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Vosoritide/ACH: New 60-Month Ph2 Data at ACMG Shows Sustained Treatment Benefit
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways from Fireside Chat with Manufacturing Executives
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Vosoritide/ACH 2-Yr Data ENDO 2021; Manufacturing Fireside Chat 3/22 4 PM ET
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Vosoritide/ACH: Ph 2 Infant/Toddler Study Enrolled & Regulatory Updates
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY20 Beat; Several Key Regulatory Catalysts Anticipated in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Roctavian/Hemophilia A - One Step Closer to Market; Selloff Overdone
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Vosoritide/ACH 2-Year Data Demonstrate Durable Treatment Effect
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: BioMarin Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Q3 Beat; Vosoritide NDA Accepted; Next, Roctavian 52-Week Phase 3 Data in Q1
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L